Liquidia Corporation (LQDA) News
Track canonical SquawkNews coverage tagged to LQDA, Liquidia Corporation. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 18 indexed stories across 13 publication days and is ordered by the same first-publication timeline used by LiveCast.
M
Liquidia: Court finds patent claims valid and infringed on YUTREPIA
Liquidia Corp said a Delaware court ruled that two claims of U.S. Patent No. 11,826,327 are valid and infringed as to YUTREPIA. The parties are expected to propose remedies.
EQUITY | Sep 30, 2026, 09:33 PM UTC
H
Liquidia Shares Plunge After Court Rules Against Lung Drug Patent
Liquidia's shares dropped nearly 50% after a federal judge ruled that its lung drug infringes a key patent held by United Therapeutics, significantly impacting the drug's commercial prospects.
REGULATION | Sep 30, 2026, 07:46 PM UTC
M
LQDA cites YUTREPIA growth and pipeline expansion powering profitability
LQDA says YUTREPIA’s launch has driven rapid revenue and patient growth, with strong adoption among naive patients and switches. It points to multiple late-stage trials, including L606, and expansion into PH-COPD and Ray
EQUITY | Sep 08, 2026, 02:20 PM UTC
M
LQDA touts commercial growth and expanding clinical pipeline
YUTREPIA launch drove rapid revenue and patient growth, with adoption in PAH and PH-ILD. The company says its pipeline is expanding, including L606 for broader indications and improved tolerability, supporting sustained
EQUITY | Sep 08, 2026, 01:43 PM UTC
M
Liquidia wins FDA Fast Track for YUTREPIA in SSc—RP
Liquidia (LQDA) received FDA Fast Track for YUTREPIA inhalation powder in SSc—RP. The company is preparing a ~75-patient Phase 2a RE—WARM trial, enrolling Oct 2026 and targeting primary completion Feb 2027.
REGULATION | Sep 07, 2026, 11:22 AM UTC
L
Liquidia gets FDA Fast Track for YUTREPIA in Raynaud's
Liquidia said the FDA granted Fast Track designation to YUTREPIA (treprostinil) inhalation powder for Raynaud’s phenomenon associated with systemic sclerosis.
REGULATION | Sep 03, 2026, 12:03 PM UTC
L
LQDA gets FDA Fast Track for YUTREPIA® in Raynaud’s
FDA granted Fast Track designation to YUTREPIA® for treating Raynaud’s phenomenon associated with systemic sclerosis.
REGULATION | Sep 03, 2026, 11:30 AM UTC
L
Liquidia to present two posters at ERS 2026 Congress
Liquidia Corporation said it will present two posters at the European Respiratory Society (ERS) 2026 Congress.
GEOPOLITICS | Sep 02, 2026, 12:37 PM UTC
H
LQDA - Liquidia to Present Posters at the European Respiratory Society (ERS) 2026 Congress
LQDA - Liquidia to Present Posters at the European Respiratory Society (ERS) 2026 Congress
GEOPOLITICS | Sep 02, 2026, 12:31 PM UTC
L
Liquidia management to speak at Wells Fargo healthcare conference
Liquidia Corporation says Michael Kaseta (COO and CFO) and Jason Adair (Chief Business Officer) will join a fireside chat at the Wells Fargo Annual Healthcare Conference.
EQUITY | Sep 01, 2026, 12:37 PM UTC
L
Liquidia to participate in Wells Fargo Annual Healthcare Conference
Liquidia Corporation said it will participate in the Wells Fargo Annual Healthcare Conference.
EQUITY | Sep 01, 2026, 12:30 PM UTC
L
LQDA Reports Second Quarter 2026 Financial Results
LQDA reports second quarter 2026 financial results
EARNINGS | Aug 12, 2026, 10:30 AM UTC
L
LQDA - Liquidia Corporation to Report Second Quarter 2026 Financial Results on August 12, 2026
LQDA - Liquidia Corporation to Report Second Quarter 2026 Financial Results on August 12, 2026
EARNINGS | Jul 29, 2026, 12:31 PM UTC
L
LQDA highs +7%
LQDA highs +7%
EQUITY | Jul 22, 2026, 03:38 PM UTC
L
Liquidia Insider Sold Shares Worth $1,053,926, According to a Recent SEC Filing
() -- Russell Schundler, General Counsel, on July 10, 2026, sold 14,738 shares in Liquidia (LQDA) for $1,053,926. Following the Form 4 filing with the SEC, Schundler has control over a total of 620,462 common shares of t
REGULATION | Jul 15, 2026, 08:07 AM UTC
L
Liquidia Insider Sold Shares Worth $1,986,695, According to a Recent SEC Filing
() -- Stephen M Bloch, Director, on July 01, 2026, sold 25,000 shares in Liquidia (LQDA) for $1,986,695. Following the Form 4 filing with the SEC, Bloch has control over a total of 926,667 common shares of the company, w
REGULATION | Jul 06, 2026, 09:48 PM UTC
M
LQDA Reports Q1
Liquidia reports first-quarter financial results with 44% sequential growth in net product sales and achieves a half-billion-dollar annualized revenue run rate for Eutrepia
EARNINGS | Jun 26, 2026, 08:35 AM UTC
M
LQDA: BTIG Raises Target
BTIG maintains buy rating on Liquidia and raises price target to $109
EQUITY | Jun 22, 2026, 10:45 AM UTC